title: Intravitreal aflibercept (A-IVI) for the treatment of neovascular age-related macular degeneration (nv-AMD): one year experience.
abstract: OBJECTIVE
  To report the anatomical and functional results of intravitreal injections of aflibercept (Eylea) (A-IVI) for the treatment of naïve eyes with neovascular age-related macular degeneration (nv-AMD).
  
  
  METHODS
  This retrospective, one-center, non-comparative chart review included 26 treatment naïve eyes with nv-AMD of 26 patients (14 male) with a mean age of 80.5 (range 63-91) who had a complete follow-up of 14 months. The morphological analysis included spectral domain optical coherence tomography and fundus fluorescein angiography, while the functional assessment included logarithm of the minimum angle of resolution (LogMAR) best correct visual acuity (BCVA). The timing of the follow-up was: baseline, 3, 6, and 14 months. All patients received 8 A-IVI according to the protocol (first 3 consecutive monthly A-IVI, followed by bi-monthly retreatment for the first year, regardless of disease activity as per local guidelines). Statistical analysis was performed using ANOVA. Improvement of visual acuity more than 15 letters was considered as "improvement", less than 5 letters as "stable" and any letter loss as "worsening".
  
  
  RESULTS
  Mean±standard deviation LogMAR visual acuity improved from 0.26±0.15 at presentation to 0.14±0.20 at the final follow-up of 14 months (P=0.02). BCVA was stable in 23.1%, improved in 61.5% (16 eyes) worsened in 15.4%. A mean pretreatment central macular thickness of 409μm reduced significantly to 229μm at month 14 (P<0.02). The OCT of eyes with worsened BCVA showed resolution of retinal fluid but presence of subretinal fibrosis. No adverse events were attributed to aflibercept.
  
  
  CONCLUSIONS
  Patients who had a worsening in visual acuity were found to have longer duration of symptoms prior to treatment and presence of geographic atrophy, and/or subretinal haemorrhage and/or subretinal fibrosis at baseline. From our experience, with 14 months follow-up, A-IVI is an effective treatment for treatment naïve patients with nv-AMD. Our real world results were similar to pivotal trials.
authors.affiliation: Department of Ophthalmology, King's College Hospital, London SE5 9RS, United Kingdom. liapapava@hotmail.com.
authors.forename: Evangelia
authors.initials: E
authors.lastname: Papavasileiou
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Zygoura
authors.forename: Theresa
authors.initials: T
authors.lastname: Richardson
authors.forename: Dominic
authors.initials: D
authors.lastname: Cortis
authors.forename: Haralabos
authors.initials: H
authors.lastname: Eleftheriadis
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Jackson